Literature DB >> 34353354

Association of cerebrospinal fluid protein biomarkers with outcomes in patients with traumatic and non-traumatic acute brain injury: systematic review of the literature.

Carlos A Santacruz1,2, Jean-Louis Vincent3, Andres Bader1, Luis A Rincón-Gutiérrez1, Claudia Dominguez-Curell1, David Communi4, Fabio S Taccone1.   

Abstract

BACKGROUND: Acute brain injuries are associated with high mortality rates and poor long-term functional outcomes. Measurement of cerebrospinal fluid (CSF) biomarkers in patients with acute brain injuries may help elucidate some of the pathophysiological pathways involved in the prognosis of these patients.
METHODS: We performed a systematic search and descriptive review using the MEDLINE database and the PubMed interface from inception up to June 29, 2021, to retrieve observational studies in which the relationship between CSF concentrations of protein biomarkers and neurological outcomes was reported in patients with acute brain injury [traumatic brain injury, subarachnoid hemorrhage, acute ischemic stroke, status epilepticus or post-cardiac arrest]. We classified the studies according to whether or not biomarker concentrations were associated with neurological outcomes. The methodological quality of the studies was evaluated using the Newcastle-Ottawa quality assessment scale.
RESULTS: Of the 39 studies that met our criteria, 30 reported that the biomarker concentration was associated with neurological outcome and 9 reported no association. In TBI, increased extracellular concentrations of biomarkers related to neuronal cytoskeletal disruption, apoptosis and inflammation were associated with the severity of acute brain injury, early mortality and worse long-term functional outcome. Reduced concentrations of protein biomarkers related to impaired redox function were associated with increased risk of neurological deficit. In non-traumatic acute brain injury, concentrations of CSF protein biomarkers related to dysregulated inflammation and apoptosis were associated with a greater risk of vasospasm and a larger volume of brain ischemia. There was a high risk of bias across the studies.
CONCLUSION: In patients with acute brain injury, altered CSF concentrations of protein biomarkers related to cytoskeletal damage, inflammation, apoptosis and oxidative stress may be predictive of worse neurological outcomes.
© 2021. The Author(s).

Entities:  

Keywords:  Cerebrospinal fluid; Neurological outcomes; Subarachnoid hemorrhage; Traumatic brain injury

Year:  2021        PMID: 34353354     DOI: 10.1186/s13054-021-03698-z

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


  45 in total

1.  NIH Roundtable on Opportunities to Advance Research on Neurologic and Psychiatric Emergencies.

Authors:  Gail D'Onofrio; Edward Jauch; Andrew Jagoda; Michael H Allen; Deirdre Anglin; William G Barsan; Rachel P Berger; Bentley J Bobrow; Edwin D Boudreaux; Cheryl Bushnell; Yu-Feng Chan; Glenn Currier; Susan Eggly; Rebecca Ichord; Gregory L Larkin; Daniel Laskowitz; Robert W Neumar; David E Newman-Toker; James Quinn; Katherine Shear; Knox H Todd; Douglas Zatzick
Journal:  Ann Emerg Med       Date:  2010-11       Impact factor: 5.721

Review 2.  CSF proteome: a protein repository for potential biomarker identification.

Authors:  Martin J Romeo; Virginia Espina; Mark Lowenthal; Benjamin H Espina; Emanuel F Petricoin; Lance A Liotta
Journal:  Expert Rev Proteomics       Date:  2005-01       Impact factor: 3.940

3.  Early CSF and Serum S100B Concentrations for Outcome Prediction in Traumatic Brain Injury and Subarachnoid Hemorrhage.

Authors:  Isabel Kellermann; Andrea Kleindienst; Nirjhar Hore; Michael Buchfelder; Sebastian Brandner
Journal:  Clin Neurol Neurosurg       Date:  2016-04-08       Impact factor: 1.876

4.  Clusterin, a New Cerebrospinal Fluid Biomarker in Severe Subarachnoid Hemorrhage: A Pilot Study.

Authors:  Norbert Wąsik; Bartosz Sokół; Marcin Hołysz; Witold Mańko; Robert Juszkat; Piotr Paweł Jagodziński; Roman Jankowski
Journal:  World Neurosurg       Date:  2017-08-09       Impact factor: 2.104

5.  Decreased cerebrospinal fluid apolipoprotein E after subarachnoid hemorrhage: correlation with injury severity and clinical outcome.

Authors:  Andrew Kay; Axel Petzold; Mary Kerr; Geoff Keir; Ed Thompson; James Nicoll
Journal:  Stroke       Date:  2003-02-13       Impact factor: 7.914

6.  The effects of 6-thioguanine and endotoxin on experimental St. Louis and Japanese B encephalitis virus infections in Chiroptera.

Authors:  B L Middlebrooks; R Allen; S E Sulin
Journal:  Proc Soc Exp Biol Med       Date:  1968-03

7.  Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction.

Authors:  J C Mertens; D Leenaerts; R Brouns; S Engelborghs; M Ieven; P P De Deyn; A-M Lambeir; D Hendriks
Journal:  J Thromb Haemost       Date:  2017-12-26       Impact factor: 5.824

8.  Microglia activation as a biomarker for traumatic brain injury.

Authors:  Diana G Hernandez-Ontiveros; Naoki Tajiri; Sandra Acosta; Brian Giunta; Jun Tan; Cesar V Borlongan
Journal:  Front Neurol       Date:  2013-03-26       Impact factor: 4.003

Review 9.  Traumatic brain injury: pathophysiology for neurocritical care.

Authors:  Kosaku Kinoshita
Journal:  J Intensive Care       Date:  2016-04-27

10.  Inflammasome proteins as biomarkers of traumatic brain injury.

Authors:  Nadine Kerr; Stephanie W Lee; Jon Perez-Barcena; Catalina Crespi; Javier Ibañez; M Ross Bullock; W Dalton Dietrich; Robert W Keane; Juan Pablo de Rivero Vaccari
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

View more
  1 in total

Review 1.  Traumatic MicroRNAs: Deconvolving the Signal After Severe Traumatic Brain Injury.

Authors:  Martin Cente; Katarina Matyasova; Nikoleta Csicsatkova; Adela Tomikova; Sara Porubska; Yun Niu; Marek Majdan; Peter Filipcik; Igor Jurisica
Journal:  Cell Mol Neurobiol       Date:  2022-07-19       Impact factor: 4.231

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.